International Psoriasis Council

subscribe
Search

Advancing Knowledge. Enhancing Care.

subscribe
Search

Advancing Knowledge. Enhancing Care.

Amgen Announces New Otezla (Apremilast) Data

news_amgen4-4-22
New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Otezla is the first and only oral therapy FDA approved in adult patients with mild, moderate, and severe plaque psoriasis.
Read Full Press Release
Amgen’s Manufacturing is Worldwide Pioneer in Biotechnology

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Psoriasis News BMS graphic

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

VIEW
Commentary -Tiago Torres

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

VIEW
Expert Insights IPC and IFPA CEO

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

VIEW

Also Read

Commentary -Tiago Torres
Biologics

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.

Read More
Tuesday, March 28, 2023

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe